Principal Pathologist-Scientist, Genentech
Relevant for
FixVUE, InSituPlex
Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.
Jena Giltnane is a translational pathologist-scientist in Genentech’s division of research and early development, where she leads digital and spatial pathology in support of translational oncology and cancer immunology programs through the use of multiplexed immunofluorescence tissue assays, tissue technology evaluation, and the collaborative development of deep learning based image analysis models in digital pathology.
Dr. Giltnane completed her MD, PhD, at Yale University in the laboratory of Dr. David Rimm and postdoctoral training in the laboratory of Dr. Carlos Arteaga at Vanderbilt University, where she also completed her Residency in Anatomic and Clinical Pathology.
She is an expert in genomic and proteomic biomarkers of diagnosis, prediction, and prognosis in breast cancer and the curation and analysis of high-dimensional clinical data.
Presented at: AACR 2022
Relevant for
Collaboration, FixVUE, Imaging mass cytometry, InSituPlex
Description This poster demonstrates a unique tissue phenotyping workflow combining three complementary methods that can unravel novel insights in the complex tumor microenvironment. The highlighted workflow delivers tissue morphology information, spatial phenotyping of immune cell population on whole slides, and high-dimensional imaging in selected regions of interest (ROIs) by combining H&E, multiplex immunofluorescence (mIF), and Imaging Mass Cytometry™(IMC™) together with bespoke data analysis.
Andrew Quong, Nina Lane, Derek Quong, Gourab Chatterjee, Devan Fleury, Kirsteen H. Maclean, Maël Manesse, Keith A. Wharton Jr, Fabian Schneider, Dan Winkowski and James Mansfield.
Senior Director Scientific Brand Strategy
Relevant for
FlexVUE, InSituPlex
Description This poster demonstrates a unique tissue phenotyping workflow combining three complementary methods that can unravel novel insights in the complex tumor microenvironment. The highlighted workflow delivers tissue morphology information, spatial phenotyping of immune cell population on whole slides, and high-dimensional imaging in selected regions of interest (ROIs) by combining H&E, multiplex immunofluorescence (mIF), and Imaging Mass Cytometry™(IMC™) together with bespoke data analysis.
Kirsty has 20 years of leadership experience addressing academic, clinical, biotechnology, clinical research organizations (CRO) and pharmaceutical industries through clinical/technical communication, sales support, and market intelligence. Most recently, Kirsty was instrumental in overseeing commercial applications for CodexDNA enabling rapid antibody development for vaccines and novel therapeutics using an automated cloning platform. Previously Kirsty held leadership roles in commercial development and scientific communications at Definiens (now part of AstraZeneca), Nanostring Technologies and ThermoFisher Scientific.She holds a PhD in Hematology and a BS (hons) in Biochemistry.
Senior Manager, FAS, North America
Relevant for
FlexVUE, InSituPlex
Description This poster demonstrates a unique tissue phenotyping workflow combining three complementary methods that can unravel novel insights in the complex tumor microenvironment. The highlighted workflow delivers tissue morphology information, spatial phenotyping of immune cell population on whole slides, and high-dimensional imaging in selected regions of interest (ROIs) by combining H&E, multiplex immunofluorescence (mIF), and Imaging Mass Cytometry™(IMC™) together with bespoke data analysis.
Kirsty has 20 years of leadership experience addressing academic, clinical, biotechnology, clinical research organizations (CRO) and pharmaceutical industries through clinical/technical communication, sales support, and market intelligence. Most recently, Kirsty was instrumental in overseeing commercial applications for CodexDNA enabling rapid antibody development for vaccines and novel therapeutics using an automated cloning platform. Previously Kirsty held leadership roles in commercial development and scientific communications at Definiens (now part of AstraZeneca), Nanostring Technologies and ThermoFisher Scientific.She holds a PhD in Hematology and a BS (hons) in Biochemistry.
Associate Director Scientific Affairs
Relevant for
FlexVUE, InSituPlex
Description This poster demonstrates a unique tissue phenotyping workflow combining three complementary methods that can unravel novel insights in the complex tumor microenvironment. The highlighted workflow delivers tissue morphology information, spatial phenotyping of immune cell population on whole slides, and high-dimensional imaging in selected regions of interest (ROIs) by combining H&E, multiplex immunofluorescence (mIF), and Imaging Mass Cytometry™(IMC™) together with bespoke data analysis.
Kirsty has 20 years of leadership experience addressing academic, clinical, biotechnology, clinical research organizations (CRO) and pharmaceutical industries through clinical/technical communication, sales support, and market intelligence. Most recently, Kirsty was instrumental in overseeing commercial applications for CodexDNA enabling rapid antibody development for vaccines and novel therapeutics using an automated cloning platform. Previously Kirsty held leadership roles in commercial development and scientific communications at Definiens (now part of AstraZeneca), Nanostring Technologies and ThermoFisher Scientific.She holds a PhD in Hematology and a BS (hons) in Biochemistry.
Presented at: AACR 2022
Relevant for
Collaboration, FixVUE, Imaging mass cytometry, InSituPlex
Description This poster demonstrates a unique tissue phenotyping workflow combining three complementary methods that can unravel novel insights in the complex tumor microenvironment. The highlighted workflow delivers tissue morphology information, spatial phenotyping of immune cell population on whole slides, and high-dimensional imaging in selected regions of interest (ROIs) by combining H&E, multiplex immunofluorescence (mIF), and Imaging Mass Cytometry™(IMC™) together with bespoke data analysis.
Andrew Quong, Nina Lane, Derek Quong, Gourab Chatterjee, Devan Fleury, Kirsteen H. Maclean, Maël Manesse, Keith A. Wharton Jr, Fabian Schneider, Dan Winkowski and James Mansfield.
Associate Director, Scientific Affairs; Senior Scientist, Visiopharm
Relevant for
Collaboration, FixVUE, InSituPlex
Description This poster demonstrates a unique tissue phenotyping workflow combining three complementary methods that can unravel novel insights in the complex tumor microenvironment. The highlighted workflow delivers tissue morphology information, spatial phenotyping of immune cell population on whole slides, and high-dimensional imaging in selected regions of interest (ROIs) by combining H&E, multiplex immunofluorescence (mIF), and Imaging Mass Cytometry™(IMC™) together with bespoke data analysis.
Kirsty has 20 years of leadership experience addressing academic, clinical, biotechnology, clinical research organizations (CRO) and pharmaceutical industries through clinical/technical communication, sales support, and market intelligence. Most recently, Kirsty was instrumental in overseeing commercial applications for CodexDNA enabling rapid antibody development for vaccines and novel therapeutics using an automated cloning platform. Previously Kirsty held leadership roles in commercial development and scientific communications at Definiens (now part of AstraZeneca), Nanostring Technologies and ThermoFisher Scientific.She holds a PhD in Hematology and a BS (hons) in Biochemistry.
Dr. Fabian Schneider is part of Visiopharm’s R&D and Product Management team, responsible for phenotyping products as well as service projects for custom APP development. Fabian has over 10 years of international experience in cancer biology and immuno-oncology, working in academic research labs, clinical research teams and computational pathology groups in both academia and biopharma. Fabian received his Dr phil. nat. in Cell Biology in 2011 from the Johan Wolfgang Goethe University Frankfurt, Germany.
Presented at: AACR 2022
Relevant for
Collaboration, FixVUE, InSituPlex
Description This poster demonstrates a unique tissue phenotyping workflow combining three complementary methods that can unravel novel insights in the complex tumor microenvironment. The highlighted workflow delivers tissue morphology information, spatial phenotyping of immune cell population on whole slides, and high-dimensional imaging in selected regions of interest (ROIs) by combining H&E, multiplex immunofluorescence (mIF), and Imaging Mass Cytometry™(IMC™) together with bespoke data analysis.
Andrew Quong, Nina Lane, Derek Quong, Gourab Chatterjee, Devan Fleury, Kirsteen H. Maclean, Maël Manesse, Keith A. Wharton Jr, Fabian Schneider, Dan Winkowski and James Mansfield.
Associate Director Scientific Affairs, Ultivue; Dept of Medical Oncology, University Hospital Brussels
Relevant for
FixVUE, InSituPlex
Description This poster demonstrates a unique tissue phenotyping workflow combining three complementary methods that can unravel novel insights in the complex tumor microenvironment. The highlighted workflow delivers tissue morphology information, spatial phenotyping of immune cell population on whole slides, and high-dimensional imaging in selected regions of interest (ROIs) by combining H&E, multiplex immunofluorescence (mIF), and Imaging Mass Cytometry™(IMC™) together with bespoke data analysis.
Kirsty has 20 years of leadership experience addressing academic, clinical, biotechnology, clinical research organizations (CRO) and pharmaceutical industries through clinical/technical communication, sales support, and market intelligence. Most recently, Kirsty was instrumental in overseeing commercial applications for CodexDNA enabling rapid antibody development for vaccines and novel therapeutics using an automated cloning platform. Previously Kirsty held leadership roles in commercial development and scientific communications at Definiens (now part of AstraZeneca), Nanostring Technologies and ThermoFisher Scientific.She holds a PhD in Hematology and a BS (hons) in Biochemistry.
Presented at: AACR 2022
Relevant for
FixVUE, InSituPlex
Description This poster demonstrates a unique tissue phenotyping workflow combining three complementary methods that can unravel novel insights in the complex tumor microenvironment. The highlighted workflow delivers tissue morphology information, spatial phenotyping of immune cell population on whole slides, and high-dimensional imaging in selected regions of interest (ROIs) by combining H&E, multiplex immunofluorescence (mIF), and Imaging Mass Cytometry™(IMC™) together with bespoke data analysis.
Presented at: AACR 2022
Relevant for
Collaboration, InSituPlex
Description This poster demonstrates a unique tissue phenotyping workflow combining three complementary methods that can unravel novel insights in the complex tumor microenvironment. The highlighted workflow delivers tissue morphology information, spatial phenotyping of immune cell population on whole slides, and high-dimensional imaging in selected regions of interest (ROIs) by combining H&E, multiplex immunofluorescence (mIF), and Imaging Mass Cytometry™(IMC™) together with bespoke data analysis.
Presented at: AACR 2022
Relevant for
Collaboration, FixVUE, InSituPlex
Description This poster demonstrates a unique tissue phenotyping workflow combining three complementary methods that can unravel novel insights in the complex tumor microenvironment. The highlighted workflow delivers tissue morphology information, spatial phenotyping of immune cell population on whole slides, and high-dimensional imaging in selected regions of interest (ROIs) by combining H&E, multiplex immunofluorescence (mIF), and Imaging Mass Cytometry™(IMC™) together with bespoke data analysis.
Presented at: AACR 2022
Relevant for
FixVUE, InSituPlex
Description This poster demonstrates a unique tissue phenotyping workflow combining three complementary methods that can unravel novel insights in the complex tumor microenvironment. The highlighted workflow delivers tissue morphology information, spatial phenotyping of immune cell population on whole slides, and high-dimensional imaging in selected regions of interest (ROIs) by combining H&E, multiplex immunofluorescence (mIF), and Imaging Mass Cytometry™(IMC™) together with bespoke data analysis.
Presented at: AACR 2022
Relevant for
Collaboration, FixVUE, InSituPlex
Description This poster demonstrates a unique tissue phenotyping workflow combining three complementary methods that can unravel novel insights in the complex tumor microenvironment. The highlighted workflow delivers tissue morphology information, spatial phenotyping of immune cell population on whole slides, and high-dimensional imaging in selected regions of interest (ROIs) by combining H&E, multiplex immunofluorescence (mIF), and Imaging Mass Cytometry™(IMC™) together with bespoke data analysis.
